Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-31.23%
operating margin TTM
-43.83%
revenue TTM
N/A
revenue per share TTM
0.0$
valuation ratios | |
|---|---|
| pe ratio | -33.56 |
| peg ratio | 0.11 |
| price to book ratio | 5.56 |
| price to sales ratio | 10.42 |
| enterprise value multiple | -31.97 |
| price fair value | 5.56 |
profitability ratios | |
|---|---|
| gross profit margin | 96.62% |
| operating profit margin | -43.83% |
| pretax profit margin | -32.12% |
| net profit margin | -31.23% |
| return on assets | -8.61% |
| return on equity | -15.12% |
| return on capital employed | -14.1% |
liquidity ratios | |
|---|---|
| current ratio | 6.12 |
| quick ratio | 6.12 |
| cash ratio | 2.02 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 13.58 |
| days of payables outstanding | 309.77 |
| cash conversion cycle | -296.19 |
| receivables turnover | 26.89 |
| payables turnover | 1.18 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.09 |
| debt equity ratio | 0.17 |
| long term debt to capitalization | 0.13 |
| total debt to capitalization | 0.14 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -0.58 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.42 |
| cash per share | 5.75 |
| operating cash flow per share | -0.35 |
| free cash flow operating cash flow ratio | 1.21 |
| cash flow coverage ratios | -0.58 |
| short term coverage ratios | -5.18 |
| capital expenditure coverage ratio | -4.85 |
Frequently Asked Questions
When was the last time Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) reported earnings?
Monte Rosa Therapeutics, Inc. (GLUE) published its most recent earnings results on 06-11-2025.
What is Monte Rosa Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE)'s trailing twelve months ROE is -15.12%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Monte Rosa Therapeutics, Inc. (GLUE) currently has a ROA of -8.61%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did GLUE's net profit margin stand at?
GLUE reported a profit margin of -31.23% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is GLUE's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.12 in the most recent quarter. The quick ratio stood at 6.12, with a Debt/Eq ratio of 0.17.